Pharmacophore pharmacophorejournal.com Pharmacophore Pharmacophore 2229-5402 pharmacophorejournal.com-6811 10.51847/pERPVY0am7 Original research Divergences in Antiviral Therapy for Diabetic Patients with COVID-19 Fitero Andreea 1 2 Negruț Nicoleta 1 2 Cseppento Delia Carmen Nistor 1 2 Tit Delia Mirela 1 3 Negru Paul Andrei 1 4 Bustea Cristian 5 Radu Andrei Flavius 1 4 Bungau Simona Gabriela 1 3 Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, Oradea 410087, Romania. Department of Psycho-Neuroscience and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, Oradea 410073, Romania. Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea 410028, Romania. Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, Oradea 410073, Romania. Department of Surgical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, Oradea 410073, Romania. Address for correspondence: Prof. Wael Abu Dayyih, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Mutah University, Al-Karak 61710, Jordan. E-mail: lnm_n10@yahoo.com 27 04 2024 15 2 79 89 Copyright: © 2026 Pharmacophore 2026 https://creativecommons.org/licenses/by-nc-sa/4.0/ This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. A<sc>BSTRACT</sc>

Patients with diabetes are particularly susceptible to COVID-19 infection, which can result in severe respiratory illness. This study conducted a comparative assessment of the impact of antiviral therapy using molnupiravir and favipiravir in COVID-19 patients with underlying diabetes. A cohort of one hundred individuals infected with SARS-CoV-2, diagnosed with diabetes, and consecutively admitted, was included in the present study. These patients were treated with antivirals according to local guidelines: Group F (51 cases) was treated with favipiravir – 10 days and Group M (49 cases) was treated with molnupiravir – 5 days. In Group F, the average hospitalization was higher than in Group M (11.29±2.27 vs. 7.14±3.16, p

 SARS-CoV-2 Favipiravir Molnupiravir Diabetes mellitus COVID-19